4-氟派醋甲酯

4-氟派醋甲酯
法律规范状态
法律规范	加：Schedule III; 德：Legal; 英：PSA;
识别信息
	IUPAC命名法 Methyl 2-(4-fluorophenyl)-2-(piperidin-2-yl)acetate; ;
CAS号	1354631-33-6
PubChem CID	70876096;
ChemSpider	26350585 ;
UNII	TN2LV2C0X9;
化学信息
化学式	C14H18FNO2
摩尔质量	251.30 g·mol−1
3D模型（JSmol（英语：JSmol））	交互式图像;
熔点	222.0 °C（431.6 °F）
	SMILES FC1=CC=C(C=C1)C(C(=O)OC)C2CCCCN2;
	InChI InChI=1S/C14H18FNO2/c1-18-14(17)13(12-4-2-3-9-16-12)10-5-7-11(15)8-6-10/h5-8,12-13,16H,2-4,9H2,1H3; Key:XISBAJBPDVRSPG-UHFFFAOYSA-N;

4-氟派醋甲酯 （4-Fluoromethylphenidate），又称4-FMPH和4F-MPH，是一种能改善使用者的专注力的药物，与哌醋甲酯相比，是一种效力较好的多巴胺再摄取抑制剂。^[2]^[3]并且成瘾性更低。

Quick Facts 法律规范状态, 法律规范 ...

Close

药理学

4-氟甲基苯甲酸甲酯与其他(±)-threo-甲基苯甲酸甲酯(TMP)类似物一起被进一步研究，以评估其作为抗可卡因药物的潜力。4F-MPH被报告为具有0.26 (0.18–0.36) mg/kg的ED₅₀，在作为可卡因替代品方面的相对效力为3.33。这是基于其对多巴胺转运蛋白的结合强度与其作为多巴胺再摄取抑制剂的活性。理论上，这将阻止一些可卡因的效果，而不会像可卡因那样上瘾。^[4] 这被误解为多巴胺与去甲肾上腺素选择性比率。

另一项研究发现，在甲基苯甲酸甲酯的threo-异构体中，带有电子吸引取代基的间位和对位化合物倾向于具有更高的结合效力。含有氟、氯、溴和甲基基团的化合物被报告比甲基苯甲酸甲酯以及密切相关的化合物4F-EPH更有效。4F-MPH被报告具有以下数值：[³H]WIN 35428结合为35.0 ± 3.0 (2) 和 [³H]多巴胺为142 ± 2.0 (2)。

^[5]

参考文献

[1]
The Drug Enforcement Administration's Special Testing and Research Laboratory Monograph (PDF). February 2017 [2023-10-01]. （原始内容存档 (PDF)于2022-06-18）.
[2]
Davies HM, Hopper DW, Hansen T, Liu Q, Childers SR. Synthesis of methylphenidate analogues and their binding affinities at dopamine and serotonin transport sites. Bioorganic & Medicinal Chemistry Letters. April 2004, 14 (7): 1799–802. PMID 15026075. doi:10.1016/j.bmcl.2003.12.097.
[3]
Misra M, Shi Q, Ye X, Gruszecka-Kowalik E, Bu W, Liu Z, et al. Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorganic & Medicinal Chemistry. October 2010, 18 (20): 7221–38. PMID 20846865. doi:10.1016/j.bmc.2010.08.034.
[4]
Schweri MM, Deutsch HM, Massey AT, Holtzman SG. Biochemical and behavioral characterization of novel methylphenidate analogs. The Journal of Pharmacology and Experimental Therapeutics. May 2002, 301 (2): 527–35. PMID 11961053. doi:10.1124/jpet.301.2.527.
[5]
Deutsch HM, Shi Q, Gruszecka-Kowalik E, Schweri MM. Synthesis and pharmacology of potential cocaine antagonists. 2. Structure-activity relationship studies of aromatic ring-substituted methylphenidate analogs. Journal of Medicinal Chemistry. March 1996, 39 (6): 1201–9. PMID 8632426. doi:10.1021/jm950697c.

[1] [1]
The Drug Enforcement Administration's Special Testing and Research Laboratory Monograph (PDF). February 2017 [2023-10-01]. （原始内容存档 (PDF)于2022-06-18）.

[2] [2]
Davies HM, Hopper DW, Hansen T, Liu Q, Childers SR. Synthesis of methylphenidate analogues and their binding affinities at dopamine and serotonin transport sites. Bioorganic & Medicinal Chemistry Letters. April 2004, 14 (7): 1799–802. PMID 15026075. doi:10.1016/j.bmcl.2003.12.097.

[3] [3]
Misra M, Shi Q, Ye X, Gruszecka-Kowalik E, Bu W, Liu Z, et al. Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorganic & Medicinal Chemistry. October 2010, 18 (20): 7221–38. PMID 20846865. doi:10.1016/j.bmc.2010.08.034.

[4] [4]
Schweri MM, Deutsch HM, Massey AT, Holtzman SG. Biochemical and behavioral characterization of novel methylphenidate analogs. The Journal of Pharmacology and Experimental Therapeutics. May 2002, 301 (2): 527–35. PMID 11961053. doi:10.1124/jpet.301.2.527.

[5] [5]
Deutsch HM, Shi Q, Gruszecka-Kowalik E, Schweri MM. Synthesis and pharmacology of potential cocaine antagonists. 2. Structure-activity relationship studies of aromatic ring-substituted methylphenidate analogs. Journal of Medicinal Chemistry. March 1996, 39 (6): 1201–9. PMID 8632426. doi:10.1021/jm950697c.

[2]

[3]

[1]

[4]

[5]